Imugene Limited
Clinical trials sponsored by Imugene Limited, explained in plain language.
A clinical-stage immuno-oncology company developing cancer therapies.
Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.
Upcoming readouts
Trials from this sponsor expected to report results within the next 12 months.
- Off-the-Shelf CAR t cells take on tough lymphomas and leukemias Results expected Jun 2027 (estimated)
-
Experimental lung cancer vaccine trial halted early
Disease control Stopped earlyThis early-stage trial tested an experimental immunotherapy called IMU-201 (PD1-Vaxx) in 24 adults with advanced non-small cell lung cancer. The treatment was given alone or combined with another immunotherapy drug (atezolizumab) and sometimes chemotherapy. The goal was to check …
Phase 1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 27, 2026 12:00 UTC
-
Cancer-Killing virus and immune drug combo tested in advanced tumors – study halted early
Disease control Stopped earlyThis early-phase study tested a new treatment for adults with advanced solid tumors that had not responded to standard therapies. The treatment combined a cancer-killing virus (onCARlytics) with an immune-boosting drug (blinatumomab), given either into the tumor or through a vein…
Phase 1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC
-
Experimental virus therapy VAXINIA tested in advanced cancer patients
Disease control Stopped earlyThis early-stage study tested a new treatment called VAXINIA (CF33-hNIS), a virus designed to attack cancer cells, in 66 adults with advanced solid tumors that had spread. The treatment was given alone or with the immunotherapy drug pembrolizumab, either as a shot into the tumor …
Phase 1 • Sponsor: Imugene Limited • Aim: Disease control
Last updated Jun 27, 2026 09:11 UTC